A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.
Phase of Trial: Phase IV
Latest Information Update: 10 Jan 2018
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Biomarker; Pharmacodynamics
- Acronyms ESTTEROD
- 04 Jan 2018 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jul 2017.
- 05 Jan 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.